Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
Collecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer. Recently, immune checkpoint inhibitors (ICI), anti-programmed death-1 (PD-1) antibody, and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody were approved for use against metastatic renal cell carc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2021/9936330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561432059707392 |
|---|---|
| author | Tetsuya Danno Shohei Iwata Fusako Niimi Sachi Honda Haruka Okada Takeshi Azuma |
| author_facet | Tetsuya Danno Shohei Iwata Fusako Niimi Sachi Honda Haruka Okada Takeshi Azuma |
| author_sort | Tetsuya Danno |
| collection | DOAJ |
| description | Collecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer. Recently, immune checkpoint inhibitors (ICI), anti-programmed death-1 (PD-1) antibody, and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody were approved for use against metastatic renal cell carcinoma. We herein described two cases of metastatic renal collecting duct carcinoma treated with a combination immunotherapy consisting of nivolumab and ipilimumab. In the first case, which included a bone metastasis, the best response achieved was stable disease (SD) for one year. In the second case, which was accompanied by a lung metastasis, the best response achieved was a partial response. The outcome of these cases suggested that the combination of nivolumab and ipilimumab is effective against renal collecting duct carcinoma. |
| format | Article |
| id | doaj-art-66498a18094d4923a62d3a7c5e6fc2b8 |
| institution | Kabale University |
| issn | 2090-696X 2090-6978 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Urology |
| spelling | doaj-art-66498a18094d4923a62d3a7c5e6fc2b82025-02-03T01:25:07ZengWileyCase Reports in Urology2090-696X2090-69782021-01-01202110.1155/2021/99363309936330Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct CarcinomaTetsuya Danno0Shohei Iwata1Fusako Niimi2Sachi Honda3Haruka Okada4Takeshi Azuma5Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, JapanDepartment of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, JapanDepartment of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, JapanDepartment of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, JapanDepartment of Pathology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, JapanDepartment of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, JapanCollecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer. Recently, immune checkpoint inhibitors (ICI), anti-programmed death-1 (PD-1) antibody, and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody were approved for use against metastatic renal cell carcinoma. We herein described two cases of metastatic renal collecting duct carcinoma treated with a combination immunotherapy consisting of nivolumab and ipilimumab. In the first case, which included a bone metastasis, the best response achieved was stable disease (SD) for one year. In the second case, which was accompanied by a lung metastasis, the best response achieved was a partial response. The outcome of these cases suggested that the combination of nivolumab and ipilimumab is effective against renal collecting duct carcinoma.http://dx.doi.org/10.1155/2021/9936330 |
| spellingShingle | Tetsuya Danno Shohei Iwata Fusako Niimi Sachi Honda Haruka Okada Takeshi Azuma Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma Case Reports in Urology |
| title | Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma |
| title_full | Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma |
| title_fullStr | Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma |
| title_full_unstemmed | Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma |
| title_short | Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma |
| title_sort | nivolumab and ipilimumab combination immunotherapy for patients with metastatic collecting duct carcinoma |
| url | http://dx.doi.org/10.1155/2021/9936330 |
| work_keys_str_mv | AT tetsuyadanno nivolumabandipilimumabcombinationimmunotherapyforpatientswithmetastaticcollectingductcarcinoma AT shoheiiwata nivolumabandipilimumabcombinationimmunotherapyforpatientswithmetastaticcollectingductcarcinoma AT fusakoniimi nivolumabandipilimumabcombinationimmunotherapyforpatientswithmetastaticcollectingductcarcinoma AT sachihonda nivolumabandipilimumabcombinationimmunotherapyforpatientswithmetastaticcollectingductcarcinoma AT harukaokada nivolumabandipilimumabcombinationimmunotherapyforpatientswithmetastaticcollectingductcarcinoma AT takeshiazuma nivolumabandipilimumabcombinationimmunotherapyforpatientswithmetastaticcollectingductcarcinoma |